Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
Sanofi Genzyme
What Does Sanofi Genzyme Do?
Sanofi Genzyme was the specialty care global business unit of Sanofi, dedicated to developing and delivering transformative therapies for patients with rare and debilitating diseases. Its core focus areas included rare diseases (such as Gaucher disease and Pompe disease), multiple sclerosis, oncology, and immunology. Genzyme Corporation, founded in 1981, was acquired by Sanofi in 2011, and its expertise significantly bolstered Sanofi's capabilities in biopharmaceuticals and specialty care. The 'Sanofi Genzyme' branding was prominent for several years before Sanofi streamlined its global business units and branding in 2022. The pioneering spirit and patient-centric approach of Genzyme continue as an integral part of Sanofi's broader operations, particularly within its Specialty Care GBU.
Where Is Sanofi Genzyme's Headquarters?
HQ Function
Served as a central site for research, development, corporate leadership, and administrative functions for Genzyme and later Sanofi Genzyme's specialty care portfolio. Continues as a key Sanofi site.
Notable Features:
Genzyme Center is renowned for its award-winning, sustainable architecture, designed by Behnisch Architekten. It features a large central atrium, extensive use of natural light, interior gardens, and environmentally conscious design elements like double-skinned curtain wall and water-saving fixtures.
Work Culture:
Historically, Genzyme (and by extension Sanofi Genzyme) fostered a deeply patient-focused and science-driven work culture. It emphasized innovation, collaboration, and a strong commitment to addressing complex medical challenges, especially in rare diseases. This ethos influenced Sanofi's specialty care operations.
HQ Significance:
This Cambridge location was instrumental in Genzyme's growth as a leading biotechnology firm and solidified the Kendall Square area's status as a preeminent biotech hub. Its legacy continues within Sanofi's extensive R&D and specialty care operations in the region.
Values Reflected in HQ: The building's design explicitly reflected Genzyme's commitment to innovation, transparency, employee well-being, community engagement, and environmental sustainability.
Location:
The operations, expertise, and product portfolio of the former Sanofi Genzyme are now fully integrated into Sanofi's extensive global network. Sanofi has a worldwide presence with research and development centers, state-of-the-art manufacturing facilities, and commercial operations across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. This global footprint ensures the continued development, production, and delivery of specialized therapies for patients in over 100 countries, maintaining the mission in critical areas like rare diseases, immunology, oncology, neurology, and rare blood disorders.
Street Address:
50 Binney Street
City:
Cambridge
State/Province:
MA
Country:
USA
Where Else Does Sanofi Genzyme Operate Around the World?
Framingham, Massachusetts, USA
Address: Sanofi, 1 The Mountain Road, Framingham, MA 01701 (One of several Sanofi sites in Framingham)
Major US operational, R&D, and manufacturing hub, supporting North American and global markets with specialized therapeutics.
Waterford, Ireland
Address: Sanofi Waterford, IDA Industrial Park, Old Kilmeaden Rd, Waterford, Ireland
Key manufacturing and supply hub for European and global markets, critical for the production of Sanofi's important biopharmaceutical medicines.
Lyon, Auvergne-Rhône-Alpes, France
Address: Sanofi has multiple sites in the Lyon area, e.g., Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France.
Central European hub for research, development, and production, critical to Sanofi's global health initiatives and supply of specialized medicines.
Buying Intent Signals for Sanofi Genzyme
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Who's Leading Sanofi Genzyme? Meet the Executive Team
As of April 2025, Sanofi Genzyme' leadership includes:
Who's Investing in Sanofi Genzyme?
Sanofi Genzyme has been backed by several prominent investors over the years, including:
What Leadership Changes Has Sanofi Genzyme Seen Recently?
Sanofi has experienced key executive transitions in the past year to 18 months, reflecting its ongoing strategic evolution ('Play to Win' strategy) and focus on innovation and growth in core therapeutic areas. These changes impact the overall direction of the company, including its specialty care activities, which carry forward the legacy of Sanofi Genzyme.
Departures
New Appointments:
What Technology (Tech Stack) Is Used bySanofi Genzyme?
Discover the tools Sanofi Genzyme uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sanofi Genzyme Email Formats and Examples
Email addresses at Sanofi, which fully integrated Genzyme, predominantly follow the standard corporate format `firstname.lastname@sanofi.com`. While legacy Genzyme email formats (e.g., @genzyme.com) existed prior to full integration, current communications and employee emails utilize the @sanofi.com domain. Variations like `firstinitial.lastname@sanofi.com` might exist in some cases but are less common.
firstname.lastname@sanofi.com
Format
olivia.chen@sanofi.com
Example
95%
Success rate
What's the Latest News About Sanofi Genzyme?
Sanofi Press Release • January 25, 2024
Sanofi News: FDA approves Dupixent® (dupilumab) as first and only biologic medicine for children aged 1 to 11 years with eosinophilic esophagitis (EoE)
The U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for children aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). This approval makes Dupixent the first and only biologic medicine indicated for this patient population. Dupixent is a flagship product in Sanofi's immunology portfolio, an area of historic strength and continued focus, building on the legacy of Genzyme's work in specialized care....more
Highperformr's free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Sanofi Genzyme, are just a search away.